Working… Menu

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02919761
Recruitment Status : Completed
First Posted : September 29, 2016
Last Update Posted : November 7, 2019
Information provided by (Responsible Party):

Brief Summary:
2 part multicenter study to examine the effect of Acthar in adult participants with rheumatoid arthritis (RA) with persistently active disease. Part 1 is an Open Label Period in which all eligible participants receive Acthar for 12 weeks. After 12 weeks of treatment with Acthar, participants will be evaluated for treatment response using the DAS28-ESR. Participants who have achieved low disease activity will enter a double-blind randomized maintenance period (Part 2) and be randomized in a 1:1 ratio to receive either Acthar or matching placebo for an additional 12 weeks.

Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Drug: Acthar Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 259 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease
Actual Study Start Date : November 7, 2016
Actual Primary Completion Date : February 2019
Actual Study Completion Date : March 20, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Open Label
Acthar 1 mL (80 U) 2x/week
Drug: Acthar
Experimental: Acthar
Acthar 1 mL (80 U) 2x/week
Drug: Acthar
Placebo Comparator: Placebo
Placebo 1 mL
Drug: Placebo

Primary Outcome Measures :
  1. Proportion of participants with Disease Activity Score with 28 joint count and Erythrocyte Sedimentation Rate (DAS28-ESR) [ Time Frame: 12 Weeks ]
    Proportion of participants with DAS28-ESR <3.2 at Week 12

Secondary Outcome Measures :
  1. Proportion of participants who maintained DAS28-ESR [ Time Frame: 24 Weeks ]
    Proportion of participants with Low Disease Activity as defined by DAS28-ESR <3.2 at Week 24

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participants must meet criteria for rheumatoid arthritis as defined by 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification at screening.
  2. Participants must have persistently active rheumatoid arthritis defined as DAS 28-ESR > 3.2 at screening.
  3. Participants must have been on a corticosteroid 12 weeks prior to screening, with a stable dose of 5-10 mg prednisone (or prednisone equivalent) for 4 weeks prior to screening.
  4. Participants must have been on either a non-biologic or biologic treatment in the 12 weeks prior to screening.

Exclusion Criteria:

  1. Participants cannot have used intra-articular steroids within 14 days of the screening visit.
  2. Participants cannot have any known contraindication to Acthar.
  3. Participants cannot have Type 1 or Type 2 diabetes.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02919761

  Show 79 Study Locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Team Leader Mallinckrodt Pharmaceutical

Layout table for additonal information
Responsible Party: Mallinckrodt Identifier: NCT02919761     History of Changes
Other Study ID Numbers: MNK14294063
First Posted: September 29, 2016    Key Record Dates
Last Update Posted: November 7, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Mallinckrodt:
persistant disease activity
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Adrenocorticotropic Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs